Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The PERSEUS trial compared bortezomib, lenalidomide, and dexamethasone (VRd) to lenalidomide, bortezomib, and dexamethasone plus daratumumab (D-VRd) in over 700 newly diagnosed, transplant-eligible multiple myeloma patients. After induction, stem cell transplant, and consolidation with the same regimens, patients in the VRd arm received lenalidomide maintenance while patients in the D-VRd armreceived daratumumab plus lenalidomide. Importantly, minimal residual disease (MRD) testing occurred, allowing therapy discontinuation in sustained MRD-negative complete responders after 2 years.
At 4 years, progression-free survival was 84.3% with D-VRd vs 67.7% with VRd (HR, 0.42), a statistically significant difference. Response rates including complete response and MRD negativity also favored D-VRd. Given the strength of these phase 3 results, D-VRd should be considered for initial induction for transplant-eligible myeloma. Adding daratumumab improves outcomes, including in the maintenance setting, while generic availability makes this affordable globally.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More